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ABSTRACT
Objective To observe intracranial pressure in women with
idiopathic intracranial hypertension who follow a low
energy diet.
Design Prospective cohort study.
Setting Outpatient department and the clinical research
facility based at two separate hospitals within the United
Kingdom.
Participants 25 women with body mass index (BMI) >25,
with active (papilloedema and intracranial pressure >25
cm H2O), chronic (over three months) idiopathic
intracranial hypertension. Women who had undergone
surgery to treat idiopathic intracranial hypertension were
excluded.
Intervention Stage 1: no new intervention; stage 2:
nutritionally complete low energy (calorie) diet
(1777 kJ/day (425 kcal/day)); stage 3: follow-up period
after the diet. Each stage lasted three months.
Main outcome measure The primary outcome was
reduction in intracranial pressure after the diet.
Secondary measures included score on headache impact
test-6, papilloedema (asmeasured by ultrasonography of
the elevation of the optic disc and diameter of the nerve
sheath, together with thickness of the peripapillary retina
measured by optical coherence tomography), mean
deviation of Humphrey visual field, LogMAR visual acuity,
and symptoms. Outcome measures were assessed at
baseline and three, six, and nine months. Lumbar
puncture, to quantify intracranial pressure, was
measured at baseline and three and six months.
Results All variables remained stable over stage 1. During
stage 2, there were significant reductions in weight (mean
15.7 (SD 8.0) kg, P<0.001), intracranial pressure (mean
8.0 (SD 4.2) cm H2O, P<0.001), score on headache impact
test (7.6 (SD 10.1), P=0.004), and papilloedema (optic
disc elevation (mean 0.15 (SD 0.23) mm, P=0.002),
diameter of the nerve sheath (mean 0.7 (SD 0.8) mm,
P=0.004), and thickness of the peripapillary retina (mean
25.7 (SD 36.1) µ, P=0.001)). Mean deviation of the
Humphrey visual field remained stable, and in only five
patients, the LogMAR visual acuity improved by one line.
Fewer women reported symptoms including tinnitus,
diplopia, and obscurations (10 v 4, P=0.004; 7 v 0,
P=0.008; and 4 v 0, P=0.025, respectively). Re-evaluation
at three months after the diet showed no significant
change in weight (0.21 (SD 6.8) kg), and all outcome
measures were maintained.
ConclusionWomen with idiopathic intracranial
hypertension who followed a low energy diet for three
months had significantly reduced intracranial pressure
compared with pressure measured in the three months
before the diet, as well as improved symptoms and
reduced papilloedema. These reductions persisted for
three months after they stopped the diet.
INTRODUCTION
Idiopathic intracranial hypertension, also known as
benign intracranial hypertension or pseudotumour
cerebri, is a condition of unknown cause characterised
by raised intracranial pressure and papilloedema.1 It
typically affects young obese women, causing dis-
abling daily headaches and loss of vision, which is
severe and permanent in up to a quarter.2 The inci-
dence of idiopathic intracranial hypertension among
obese women is 20 per 100 000, and the prevalence is
predicted to rise in conjunction with the global epi-
demic of obesity.3
There is insufficient evidence to guide therapeutic
strategies, as highlighted in the 2005 Cochrane
review.4 The condition has a striking association with
obesity (greater than 93%),5 and consequently weight
loss is often suggested as a treatment. Nevertheless,
there has been only one previous prospective weight
modifying study, carried out 35 years ago, which
observed subjective improvement in the papilloedema
in nine patients on a low calorie rice diet6; these
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findings were supported by retrospective review of
case notes.7-9 These studies relied on subjective obser-
vation of papilloedema and included people with
newly diagnosed idiopathic intracranial hypertension,
many of whom improve irrespective of any treatment
given. Furthermore, they did notmonitor concomitant
changes in intracranial pressure with either weight loss
or resolution of papilloedema.
We carried out a detailed examination of the inter-
play between weight loss in patients with idiopathic
intracranial hypertension with objective measures of
papilloedema and visual function, headache scores
and, crucially, changes in intracranial pressure.
METHODS
Participants
Women with idiopathic intracranial hypertension
were identified and recruited from the Birmingham
and Midland Eye Centre, University Hospitals Bir-
minghamNHSFoundationTrust, andUniversityHos-
pitals of Leicester NHS Trust. Idiopathic intracranial
hypertensionwas diagnosed according to themodified
Dandy criteria,10 with all patients having normal find-
ings on magnetic resonance imaging and venography,
papilloedema, intracranial pressure >25 cmH2O, and
duration of disease over three months at enrolment.
Women were excluded if they had undergone pre-
vious cerebrospinal fluid diversion or optic nerve
sheath fenestration, were pregnant or planning to con-
ceive, had relevant comorbidity, or were aged less than
16. All women who met the inclusion criteria were
invited to take part in the study.
Study design
Twenty five women were prospectively recruited into
a three stage study. Stage 1was a threemonth period of
no new intervention (control phase); stage 2 comprised
a three month intensive diet; and stage 3 was a three
month follow-up after completion of the diet (fig 1).
Weight loss was achieved with a previously
validated,11 nutritionally complete, low energy, total
meal replacement liquid diet (Lipotrim,HowardFoun-
dation, Cambridge), which provided women with a
total of 1777 kJ/day (425 kcal/day). Patients were
advised to consume no additional food, and drink at
least 2 litres of fluid a day. During stage 2 all partici-
pants underwentweekly review conducted at theWell-
comeTrust Clinical Research Facility at theUniversity
Hospitals Birmingham NHS Foundation Trust. Com-
pliance with the diet was monitored through evalua-
tion of weight lost and presence of urinary ketones (a
feature of abstaining from food intake). Participants
were also regularly encouraged, through the provision
of weekly nutritional counselling.
Participants were evaluated at baseline and at the
end of each stage. Anthropometric data were collected
and body mass index (BMI) calculated. The presence
of symptoms (tinnitus, visual loss, diplopia, visual
obscurations, and headache) together with medication
use was recorded. Assessment of visual function under
standardised luminescence was carried out with a Log-
MAR (log of theminimum angle of resolution) chart to
assess visual acuity, automated perimetry (Humphrey
24-2 central threshold) to measure the visual field
mean deviation, a Pelli-Robson chart to evaluate con-
trast sensitivity, and a Farnsworth-Munsell 100 hue test
to appraise colour vision. (See appendixAon bmj.com
for details.)
Papilloedemawas evaluated withmasked ultrasono-
graphy of the optic disc elevation and nerve sheath
diameter (maximal retrobulbar pial diameter) by
using a high resolution brightness scan (B-scan) with
emission frequency 20MHz and 10MHz, respectively
(Quantel Medical, Clermont-Ferrand, France). Addi-
tionally, peripapillary retinal nerve fibre layer thick-
ness was measured by optical coherence tomography
(Stratus OCT V4.0.1, Carl Zeiss, Meditec, Welwyn
Garden City). At each visit a neuro-ophthalmologist
carried out masked papilloedema grading of fundus
photographs (Frisen rating scale 0 to 5, the latter
being most severe (see appendix B on bmj.com).12
Headache phenotype (according to criteria from the
International Headache Society)13 was assessed at base-
line. Women completed a daily headache diary in the
Enrol
0 months
Stage 1 No new intervention
3 months
Stage 2 Weight loss (diet)
6 months
9 months
Stage 3 Follow up
Outcome measures assessed:
  Intracranial pressure (lumbar puncture)
  Headache impact test-6
  Vision assessments
  Symptomatic evaluation
Fig 1 | Summary of study design. Vision assessments include
measurement of papilloedema by ultrasonographic evaluation
of optic disc elevation and nerve sheath diameter as well as
optical coherence tomography measurement of retinal nerve
fibre layer, LogMAR visual acuity, Humphrey visual field 24-2
mean deviation, Pelli-Robson contrast sensitivity, and
Farnsworth-Munsell 100 hue colour assessment. Symptoms
evaluated include headache, tinnitus, visual loss,
obscurations and diplopia. Lumbar puncture was carried out
only at baseline, three and six months
Table 1 | Baseline demographics in 25 women with idiopathic
intracranial hypertension before starting low energy diet
Data
Mean (SD) age (years) 34.4 (9.2)
Ethnicity:
White 20
African-Caribbean 3
South West Asian (Indo-Pakistani) 2
Mean (SD) duration of disease (months) 39.0 (49.2)
Taking acetazolamide 11
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week before each visit, in which they evaluated severity
with a visual analogue pain scale (0-10), headache fre-
quency (days/week), and use of analgesia (days/week).
The women also completed a headache questionnaire
(headache impact test-6 score range 36-78).14
Intracranial pressurewasmeasuredby lumbar punc-
ture at baseline and at the end of stages 1 and 2 after all
listed outcome measures had been assessed. Measure-
ments were taken with the patient breathing steadily in
the left lateral position, legs extended greater than 90°
at the hip, with adequate time taken to ensure a stable
reading.
Statistical analysis
Statistical analysis was performed with SPSS for Win-
dows version 15.0 (SPSS, Chicago, IL) and Prism for
Windows version 5.0 (GraphPad Software Inc, San
Diego, CA) software packages. Data were reported
with means and standard deviations. Serial measure-
ments were analysed with repeated measures: analysis
of variance (for parametric or log transformed data) or
Friedman’s test, with post hoc evaluation achieved
with a Wilcoxon signed rank test (for non-parametric
data). We analysed dichotomous variables with a
Cochran’sQ test, and evaluated changes in categorical
data with the sign test. Associations between clinical
parameters and objective outcome measures were
analysed with Pearson’s correlation for parametric
data and Spearman’s rank correlation for non-para-
metric data. Data were analysed only if present at all
time points for each individual. The level at which the
results were judged significant was P<0.05 (or P<0.017
for Wilcoxon signed rank test and Sign test as three
pairwise comparisons were being made per variable).
As data for the right and left eye correlated significantly
and yielded analogous results, we have presented only
right eye data.
RESULTS
Of 37 women identified, 25 agreed to take part and 12
declined because of concerns about repeated lumbar
puncture. All 37 women had homogeneous character-
istics. Among those who agreed to take part, one
woman was subsequently excluded as she was found
to have a secondary cause of raised intracranial pres-
sure, two did not complete stage 2 of the study as they
could not tolerate the diet, and two were lost to follow-
up at the final study visit. Women who withdrew from
the study had similar clinical and anthropometric char-
acteristics to those remaining in the study. Table 1
shows participants’ demographics. During the study
11 (44%) patients received an unchanging dose of acet-
azolamide. No other drugs for idiopathic intracranial
hypertension were used. There were minimal side
Table 2 | Study characteristics and symptom chronology at each assessment. Figures are means (SD) unless stated otherwise
Characteristic Baseline Start diet End diet Final P value*
Weight (kg) 101.5 (16.0) 102.5 (16.8) 86.8 (15.6) 87.0 (12.9) <0.001
BMI 38.2 (5.0) 38.6 (5.3) 32.6 (4.7) 32.8 (4.4) <0.001
Intracranial pressure (cm H2O) 39.8 (5.1) 38.0 (5.0) 30.0 (4.9) — <0.001
Vision:
Optic disc elevation (ultrasonography) (mm) 1.02 (0.30) 0.97 (0.31) 0.82 (0.28) 0.75 (0.26) 0.002
Optic nerve sheath diameter (ultrasonography) (mm) 4.5 (1.0) 4.7 (1.0) 4.0 (1.2) 3.6 (1.2)† 0.004
Retinal nerve fibre layer distension (optical coherence tomography) (µm)‡ 144.1 (45.5) 135.0 (48.0) 109.3 (27.9) 108.2 (28.6) 0.001
LogMAR visual acuity§ −0.02 (0.10) 0.01 (0.11) −0.06 (0.09) −0.07 (0.08) <0.001†
Pelli-Robson contrast sensitivity§ 1.58 (0.17) 1.61 (0.11) 1.67 (0.05) 1.68 (0.10) 0.003
Humphrey visual field 24-2 mean deviation§ −3.8 (4.1) −3.4 (3.7) −2.7 (3.0) −1.5 (1.8)† 0.162
Farnsworth-Munsell 100 hue colour assessment‡ 110.7 (86.5) 89.3 (84.6)¶ 65.7 (54.9)¶ 61.3 (62.0)¶ 0.027
Headache:
Impact test (HIT-6)§ 57.5 (9.0) 54.5 (1.0) 46.9 (10.1) 48.4 (9.6) 0.004
Severity (VAS score 0-10)§ 3.8 (2.4) 4.2 (2.8) 1.9 (2.8) 2.6 (2.7) 0.015
Frequency (days/week)§ 3.8 (2.9) 4.4 (2.9) 2.1 (2.8) 2.6 (3.1) 0.011
Analgesic use (days/week)§ 2.2 (2.7) 2.2 (2.5) 0.2 (0.4) 1.0 (2.1) 0.007
No (%) with symptoms:
Headache** 19 (95) 19 (95) 12 (60) 10 (50) <0.001
Tinnitus** 10 (50) 10 (50) 4 (20) 4 (20) 0.004
Visual loss** 8 (40) 7 (35) 3 (15) 1 (5) 0.063
Obscurations** 3 (15) 4 (20) 0 (0) 0 (0) 0.025
Diplopia** 0 (0) 7 (35) 0 (0) 0 (0) 0.008
BMI=body mass index; LogMAR=log of minimal angle of resolution; HIT-6=headache impact test-6; VAS=visual analogue score.
*Summary statistics represent values for women who completed study (n=20). P values indicate changes after weight reduction (start diet v end diet; stage 2). No significant changes were
noted from baseline to start diet (stage 1) or from end diet to final visit (stage 3) unless indicated.
†Significant improvement noted but not found in left eye.
‡Data logged before analysis.
§Friedman’s test used for analysis. If result was significant, Wilcoxon sign rank test subsequently carried out, results of latter quoted in table.
¶Significant change noted after each stage, therefore weight loss stage did not significantly improve variable. All data analysed (at four time points, except intracranial pressure, which was
analysed at three time points) with repeated measures analysis of variance unless stated otherwise.
**Cochran’s Q test showed significant improvement in all variables; sign test subsequently used to evaluate differences at each study stage.
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effects associated with the low energy diet: constipa-
tion (three patients), light headed feelings (ameliorated
by increased fluid intake) (two), and halitosis (one).
None of the women underwent diversion of cerebro-
spinal fluid or fenestration of the optic nerve sheath
during the study.
Twenty women completed the entire study and
formed the cohort for the analyses. At baseline, mean
valueswere 101.5 (SD16.0) kg forweight, 38.2 (5.0) for
BMI, and 39.8 (5.1) cm H2O for intracranial pressure
(table 2). Universal papilloedema was confirmed with
ultrasonography and optical coherence tomography,
the most common grade being Frisen grade 2 (16 of
20 cases), with the remainder grade 1 (4 of 20 cases).
There was minimal evidence of visual loss, with mean
LogMAR acuity of −0.02 (SD 0.10) and mean Hum-
phrey visual field mean deviation of −3.8 (SD 4.1)
(that is, a low deviation from the variance observed in
the general population). Eightwomendescribed symp-
toms of visual loss (such as blurred or distorted vision
and blind spots). At the start of the diet three women
reported visual obscurations, and 10 reported tinnitus.
Seven reported diplopia at the beginning of stage 2.
Headache was almost universally reported (19 of 20
patients) and represented a major source of morbidity
(mean headache impact test-6 score 57.5, SD 9.0).
Baseline headache phenotyping indicated that 12 out
of 20 women had migrainous headache (International
Headache Society (IHS) classification 1.1, 1.2, and
1.5.1) in addition to headache attributed to idiopathic
intracranial hypertension (IHS 7.1.1) and seven
described medication overuse. 13
As expected, none of the measured variables altered
significantly during stage 1 (no intervention). After the
low energy diet (stage 2), mean weight fell by 15.7
(SD 8.0) kg (P<0.001; −15.3% (SD 7.0%) of weight)
and mean intracranial pressure by −8.0 (SD 4.2) cm
H2O (P<0.001) (fig 2).[f2] Although all women lost
weight and reduced their intracranial pressure, the
change in pressure during the low energy diet did not
correlate with change in weight (r=0.280, P=0.209) nor
with changes in any of the other outcome measures.
Figure 3 shows that all three measurements used to
objectively evaluate different aspects of papilloedema
significantly improvedafterweight loss (stage 2): eleva-
tion of the optic disc (P=0.002), diameter of the optic
nerve sheath (P=0.004), and thickness of peripapillary
retinal nerve fibre layer (P=0.001). There was, how-
ever, no significant improvement in the less discrimi-
nating Frisen grade during stage 1 or 2. The actual
LogMAR visual acuity score improved significantly
(P<0.001), but this equated to an improvement of
only one line (0.1) in five women and was not consid-
ered clinically relevant. The Pelli-Robson contrast sen-
sitivity score improved significantly after weight loss
(stage 1: four patients improved, two deteriorated;
stage 2: eight patients improved, one deteriorated;
P=0.003). During the course of the study, we also
noted small improvements in Humphrey visual field
mean deviation (0.4 (SD 1.6) for stage 1 (P=0.110)
and 0.7 (SD 2.4) for stage 2 (P=0.162)) and Farns-
worth-Munsell colour assessment (−21.4 (SD 49.7)
for stage 1 (P=0.012) and −23.6 (SD 45.3) for stage 2
(P=0.027)). This reflects a learning effect in participants
and not a response to weight reduction.15
Headache (measured by headache impact test-6) sig-
nificantly improved after weight loss to a score of 46.9
(SD 10.1) (P=0.004) (fig 4). Figure 4 also shows signifi-
cant improvements in headache severity (visual
analogue pain score from 4.2 (SD 2.8) to 1.9 (SD 2.8),
P=0.015), headache frequency (from4.4 (SD2.9) to 2.1
(SD 2.8) days a week, P=0.011), and weekly use of
analgesics (from 2.2 (SD 2.5) to 0.2 (SD 0.4) days a
week, P=0.007) (table 2). Patients’ symptoms (head-
ache, tinnitus, obscurations, and diplopia) showed sig-
nificant improvement after the lowenergydiet (stage 2)
(P<0.001, P=0.004, P=0.025, and P=0.008, respec-
tively) (table 2).
At the final visit threemonths after the end of the diet
(end of stage 3, table 2), all outcome measures includ-
ing weight (0.2 (SD 2.5) kg, P=0.894) were unchanged,
with the exception of headache symptoms (P=0.002),
papilloedema (nerve sheath diameter −0.4 (SD 0.8)
mm, P=0.035, and disc elevation −0.07 (SD 0.15)
mm, P=0.059), and mean deviation of the Humphrey
visual field (1.2 (SD 2.0), P=0.009), which continued to
improve.
DISCUSSION
In this small prospective study, womenwith idiopathic
intracranial hypertension who followed a low energy
(calorie) diet for three months had significantly
reduced intracranial pressure compared with pressure
measured in the three months before the diet (head-
aches and papilloedema also significantly improved).
In the three months after the diet ended, weight loss
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wasmaintained and improvements in headache, papil-
loedema, and vision persisted. These findings suggest
that weight reducing diets can help in themanagement
of idiopathic intracranial hypertension.
In four of the 20 women, intracranial pressure fell to
a “normal” level (below 25 cmH2O). In the 16 women
whose intracranial pressure remained above 25 cm
H2O, 13 became asymptomatic for tinnitus, visual
loss, diplopia, and visual obscurations after weight
loss, compared with four at baseline. These data high-
light that itmight not be necessary for peoplewith idio-
pathic intracranial hypertension to reduce their
intracranial pressure to below defined normal levels
to achieve measurable symptomatic relief. This
might, however, be an overly simplistic concept as
obesity is known to marginally increase intracranial
pressure,16 and the equilibrium of cerebrospinal fluid
dynamics in resolving idiopathic intracranial hyper-
tension might be re-set such that apparent normality
occurs at higher pressures. There was also an absence
of a direct relation between weight loss and change in
intracranial pressure, potentially suggesting a more
complex relation, which could be influenced by a
weight threshold for raised intracranial pressure in
individual patients.
Measured variables
Papilloedema, objectively measured with optical
coherence tomography, ultrasonography of optic disc
elevation, and optic nerve sheath diameter, as well as
symptoms (headache, tinnitus, obscurations, and
diplopia), all significantly improved after the low
energy diet. Papilloedema continued to resolve during
stage 3, despiteweight remaining stable. This probably
reflects a relatively slow resolution of optic disc axonal
distension and oedema after reduction in intracranial
pressure. Delayed resolution of papilloedema is also
noted after normalisation of intracranial pressure
after cerebrospinal fluid shunting for idiopathic intra-
cranial hypertension (that is, the papilloedema resolves
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over a period ranging from three weeks to seven
months after surgery).17 The headache impact score,
which was substantial at baseline (57.5 (SD 9.0)), sig-
nificantly improved after the low energy diet (P=0.004)
to a level that had no or little impact on daily life (46.9
(SD 10.1)) (disability quantification from www.heada
chetest.com/HIT6translations.html).18 A subgroup of
women (eight out of 20) continued to report disabling
headaches after the diet, characterised by a score of
>50 on the headache impact test-6, despite a reduction
inweight and intracranial pressure equivalent to that of
the whole study cohort. Alternative headache pheno-
types such as migraine could account for the headache
morbidity in these women.
The extent of weight reduction (loss of over 15% of
body weight) is important as numerous other weight
loss strategies had previously failed in these women.
The low energy diet entailed consumption of three
low energy nutrition drinks a day, which varied in fla-
vour. Compliance and consequent universal effective-
ness of the diet reflected patients’ satisfaction with the
regime. This was attributed to the individual weekly
review sessions; weekly evidence of successful weight
loss, a dependable consequence of consuming only
1777 kJ/day (425 kcal/day), and a powerfulmotivating
factor; and ketosis, which enhanced hypothalamic sati-
ety, reducing hunger and food cravings once the diet
was established. The struggle for patients to achieve
andmaintainweight reductionhowever, is, universally
recognised.Weight loss through low energy diets, gra-
dual energy restriction, or exclusion of macronutrients
(fat, carbohydrates, or protein) couldbe a little as 2-4 kg
at two years.19 Other non-dietary strategies to encou-
rage weight loss include pharmacological and surgical
interventions. Pharmacological treatment for obesity,
despite tolerability, is unlikely to achieve sufficient
weight loss to greatly modify idiopathic intracranial
hypertension. After 12 months’ treatment, mean
weight loss is 2.89 kg with orlistat20 and 4.45 kg with
sibutramine.21 Additionally, after concerns about
cardiovascular risk, the European Medicines Agency
recently withdrew the prescribing licence for sibutra-
mine and theNational Institute forHealth andClinical
Excellence (NICE) withdrew recommendations for its
use.22 Topiramate might be amore useful weight mod-
ifying drug (reduces weight by 9.75 kg at 12 months in
patients with idiopathic intracranial hypertension),23
with additional potential to reduce cerebrospinal fluid
secretion via carbonic anhydrase inhibition24 and effi-
cacy in treating coexisting migraine. Bariatric surgery
could be effective, and one study reported a resolution
of papilloedema in a series of eight patients.25Although
the advantage of this approach has previously been
limited by unacceptablemorbidity, recent studies indi-
cate improved safety and efficacy of laparoscopic bar-
iatric surgery and provide rationale for the re-
evaluation of this technique in people with idiopathic
intracranial hypertension.26
Strengths and weaknesses
This was a small study with only 25 patients, which
inevitably leads to limitations in interpretation.
Because of the intensity of the low energy diet inter-
vention and the detailed clinical protocol, however,
performing a study in large numbers of patients before
this prospective cohort studymight not have been ethi-
cally viable.
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Evaluation of papilloedema in previous therapeutic
studies of idiopathic intracranial hypertension has
relied on subjective observation; our use of previously
described objective imaging measures27 28 marks an
important advance in gauging optic disc swelling that
will enhance research and contribute to future clinical
trial design. We acknowledge that lumbar puncture,
which records only a snapshot assessment of intra-
cranial pressure, is not as accurate as 24 hour continu-
ous monitoring, which reflects diurnal fluctuations in
intracranial pressure. The minimal changes in intra-
cranial pressure reported over stage 1 (−1.8 (SD 5.5)
cm H2O without intervention), however, indicate
that the variability in intracranial pressure did not sig-
nificantly influence our data. We recognise that the
non-randomised controlled nature of our study design
needs to be taken into account when evaluating these
data. Patients’ acceptability and ethical considerations
prevented recruitment to a control cohort (which
would require serial lumbar puncture—a procedure
with associated morbidity). Although our study, like
other observational case series, might have been
prone to unrecognised bias, confounding factors, or,
potentially, overestimation of therapeutic magnitude,
a rigorous study design like ours can minimise these
potential limitations.29 A major strength of this study
is that all patients had chronic stable idiopathic intra-
cranial hypertension (mean disease duration 39.0 (SD
49.2) months). This reduced the risk of bias from the
possibility of rapid spontaneous resolution, which is a
recognised phenomenon in some patients with acute
idiopathic intracranial hypertension. A consequence
of selecting a chronic cohort was that visual impair-
ment was minimal and papilloedema was mild (Frisen
grades all ≤2) inmost women at enrolment.We did not
include patients with a history of rapidly declining
vision requiring cerebrospinal fluid diversion surgery
or other aggressive treatment. Visual function (Log-
MAR score andHumphrey visual field) was preserved
at baseline in our participants, and a clinically impor-
tant improvement was not noted nor expected.
Despite studying a cohort with chronic idiopathic
intracranial hypertension, we observed clinically and
statistically significant improvements in symptoms
and papilloedema.
Comparison with other studies
The only previous prospective study of therapeutic
weight loss in idiopathic intracranial hypertension
merely assessed subjective changes in papilloedema
and included only nine patients.6 We not only used
objective measures to quantify changes in papilloe-
dema but additionally observed intracranial pressure
in patients after a low energy diet.
Implications and future research
After a low energy diet, women with idiopathic intra-
cranial hypertension had significantly reduced intra-
cranial pressure, headaches, and papilloedema. Our
findings suggest that advising and encouraging such
patients to embark on and maintain a weight reducing
diet could be of therapeutic benefit.Weight loss clinics
could have a role in the management of idiopathic
intracranial hypertension, though the long term effec-
tiveness and heath economics of this approach will
require critical evaluation in a further study comparing
weight reduction using NHS dieticians with specially
designated weight reduction clinics for patients with
idiopathic intracranial hypertension.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Over 93% of patients with idiopathic intracranial hypertension are obese
Weight loss is a commonly advocated treatment for idiopathic intracranial hypertension, but
there is little prospective evidence for efficacy
WHAT THIS STUDY ADDS
Weight reduction in women with idiopathic intracranial hypertension was associated with
reduced intracranial pressure (measured by lumbar puncture), papilloedema, and symptoms
including headache
Encouraging patients with idiopathic intracranial hypertension to embark on and maintain a
weight reducing diet might be helpful
The use of objective imaging measures to quantify papilloedema in idiopathic intracranial
hypertension mark an important advance that will enhance clinical care and contribute to
design of future clinical trials
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